HLTW:PA:PA-Multi Units Luxembourg - Lyxor MSCI World Health Care TR UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 426.99

Change

0.00 (0.00)%

Market Cap

USD 0.72B

Volume

613.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The Sub-Fund is an index-tracking UCITS passively managed. The Reference Currency of the Sub-Fund is the Euro (EUR). The investment objective of sub-fund is to track both the upward and the downward evolution of the MSCI World Health Care Index " Net Total Return (the Index) denominated in US Dollars - while minimising the volatility of the difference between the return of the Sub-Fund and the return of the Index (the "Tracking Error"). The anticipated level of the tracking error under normal market conditions is expected to be up to 0.50%.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

ETFs Containing HLTW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.76% 31% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.76% 31% F 33% F
Trailing 12 Months  
Capital Gain -8.58% 12% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.58% 12% F 34% F
Trailing 5 Years  
Capital Gain 27.56% 33% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.56% 32% F 45% F
Average Annual (5 Year Horizon)  
Capital Gain 9.66% 59% D- 65% D
Dividend Return 9.66% 60% D- 63% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.89% 68% D+ 84% B
Risk Adjusted Return 108.72% 90% A- 92% A
Market Capitalization 0.72B 72% C 74% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike